Mosunetuzumab Retreatment is Effective and WellTolerated in Patients with Relapsed/Refractory B-cell non-Hodgkin Lymphoma

被引：0
|
作者：
Cheah, Chan Yoon [1 ,2 ]
Nancy, Bartlett L. [3 ]
Sarit, Assouline E. [4 ]
Stephen, Schuster J. [5 ]
Kim, Won Seog [6 ]
Shadman, Mazyar [7 ]
Isufi, Iris [8 ]
Yin Shen [9 ]
Michelle, Doral Y. [9 ]
Sit, Jason [9 ]
Chen, Vivian [9 ]
Huang Huang [10 ]
Zhou Mingzhu [11 ]
Michael, Wei C. [9 ]
Budde, L. Elizabeth [12 ]
机构：
[1] Sir Charles Gairdner Hosp, Linear Clin Res, Perth, WA, Australia
[2] Univ Western Australia, Perth, WA, Australia
[3] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA
[4] Jewish Gen Hosp, Montreal, PQ, Canada
[5] Univ Penn, Philadelphia, PA 19104 USA
[6] Samsung Med Ctr, Seoul, South Korea
[7] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[8] Yale Sch Med, New Haven, CT USA
[9] Genentech Inc, San Francisco, CA 94080 USA
[10] Hoffmann La Roche Ltd, Mississauga, ON, Canada
[11] F Hoffmann La Roche Ltd, Shanghai, Peoples R China
[12] City Hope Natl Med Ctr, Duarte, CA USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-071
引用
收藏
页码：S44 / S45
页数：2
相关论文
共 50 条
  • [1] Mosunetuzumab Retreatment Is Effective and Well-Tolerated in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
    Cheah, Chan Yoon
    Bartlett, Nancy L.
    Assouline, Sarit
    Schuster, Stephen J.
    Kim, Won Seog
    Shadman, Mazyar
    Isufi, Iris
    Yin, Shen
    Doral, Michelle Y.
    Sit, Jason
    Chen, Vivian
    Huang, Huang
    Zhou, Mingzhu
    Wei, Michael C.
    Budde, L. Elizabeth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S455 - S455
  • [2] Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma
    Bender, Brendan
    Li, Chi-Chung
    Marchand, Mathilde
    Turner, David C.
    Li, Feifei
    Vadhavkar, Shweta
    Wang, Bei
    Deng, Rong
    Lu, James
    Jin, Jin
    Li, Chunze
    Yin, Shen
    Wei, Michael
    Chanu, Pascal
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (06):
  • [3] Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
    Witzig, TE
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (Suppl 1) : S91 - S95
  • [4] Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
    Thomas E. Witzig
    Cancer Chemotherapy and Pharmacology, 2001, 48 : S91 - S95
  • [5] Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma
    Mohty, Razan
    Vanegas, Yenny Moreno
    Chavez, Julio C.
    Kharfan-Dabaja, Mohamed A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (02) : 121 - 126
  • [6] Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma
    Moleti, Maria L.
    Testi, Anna M.
    Foa, Robin
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (05) : 826 - 843
  • [7] POPULATION PHARMACOKIN ETICS OF ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
    Padros, M. Bravo
    Conrado, D.
    Zhu, M.
    Srinivasan, K.
    Meng, X.
    Yan, H.
    Davis, J.
    Harnisch, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S69 - S69
  • [8] Managing Cytokine Release Syndrome and Neurotoxicity with Step-Up Dosing of Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
    Bartlett, Nancy L.
    Sehn, Laurie H.
    Assouline, Sarit
    Bosch, Francesc
    Diefenbach, Catherine M.
    Flinn, Ian
    Hong, Jung Yong
    Kim, Wonseog S.
    Matasar, Matthew
    Nastoupil, Loretta
    Schuster, Stephen J.
    Shadman, Mazyar
    Yoon, Sung-Soo
    Bender, Brendan
    Chu, Wayne
    Hernandez, Genevive
    Kwan, Antonia
    McCall, Bruce
    Sison, Iris
    Wang, Cunlin
    Wei, Michael C.
    Yin, Shen
    Yousefi, Kasra
    Budde, Elizabeth L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S247 - S247
  • [9] Radioimmunotherapy for Indolent B-Cell Non-Hodgkin Lymphoma in Relapsed, Refractory and Transformed Disease
    Otto J. Visser
    Lars R. Perk
    Josée M. Zijlstra
    Guus A.M.S. van Dongen
    Peter C. Huijgens
    Arjan A. van de Loosdrecht
    BioDrugs, 2006, 20 : 201 - 207
  • [10] Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease
    Visser, Otto J.
    Perk, Lars R.
    Zijlstra, Josee M.
    van Dongen, Guus A. M. S.
    Huijgens, Peter C.
    van de Loosdrecht, Arjan A.
    BIODRUGS, 2006, 20 (04) : 201 - 207
12345